Close menu




June 27th, 2022 | 12:12 CEST

BrainChip and Palantir with strong rebound - How does BioNTech react?

  • chips
  • Technology
  • Biotechnology
Photo credits: pixabay.com

The correction on the stock markets has been going on for months. Technology stocks, in particular, have been hit hard. Due to the end of the ultra-loose monetary policy and possible larger interest rate steps, even market leaders lost more than 80% of their ground in some cases. Whether interest rate hikes can be implemented as planned in the coming months, on the other hand, appears more than questionable. After all, the spectre of recession is already hovering over the capital markets. Moreover, the historical debt levels of several countries are likely to rule out further interest rate hikes.

time to read: 4 minutes | Author: Stefan Feulner
ISIN: BRAINCHIP HOLDINGS LTD | AU000000BRN8 , PALANTIR TECHNOLOGIES INC | US69608A1088 , BIONTECH SE SPON. ADRS 1 | US09075V1026

Table of contents:


    BrainChip Holdings - Classic setback offers opportunity

    Unlike Netflix, Zoom or other tech industry giants, the developer of the Akida chip, Australia's BrainChip Holdings, is showing resilience. The share price performance of the emerging IP company, which is the world's first commercial manufacturer of neuromorphic AI chips, has been in the green since the beginning of the year. After starting the year at EUR 0.45, it went up to EUR 1.66 on the back of news related to a cooperation with car giant Mercedes. It was announced that Akida technology would make the "Hey, Mercedes" voice control in the EQXX five to ten times more efficient than conventional voice control. Since then, however, the share has corrected by almost 70% due to the weak market environment. However, a bottom is currently being formed in the EUR 0.60 area. In addition, MACD and RSI are close to a buy signal.

    In the long term, BrainChip's novel AI chip could become the new standard in the semiconductor market. The advantages are that Akida is extremely low-power, high-performance, and promotes the growth of edge AI technology by using neuromorphic architecture, a type of artificial intelligence inspired by the biology of the human brain. BrainChip enables the universal use of efficient edge computing in real-world applications such as connected cars, consumer electronics and the Internet of Things. It is no coincidence that BrainChip has been accepted into chip giant ARM's partner program, enabling research into the next generation of AI solutions.

    Another new partnership is with the inventor of the world's most advanced neuromorphic vision systems, Prophesee. Prophesee's technology is inspired by human vision. It uses a patented sensor design and AI algorithms that mimic the eye and brain to detect what was previously invisible with standard image-based technology. Prophesee's computer vision systems, like Akida, target segments such as autonomous vehicles, industrial automation, IoT, security and surveillance, augmented reality, and virtual reality.

    "We have successfully ported Prophesee's neuromorphic-based camera sensor data to process inferences on Akida with impressive performance," said Anil Mankar, Co-Founder and CDO of BrainChip. "This combination of intelligent vision sensors with Akida's ability to process data with unprecedented efficiency, precision and power savings at the point of capture is a true advancement in AI and provides manufacturers with an immediately actionable solution."

    Palantir with trend reversal

    The stock of data analytics specialist Palantir has been actively working to bottom out in recent weeks. After losing around 88% and marking a new all-time low of USD 6.44 after the quarterly figures were announced, the stock is steadily climbing. Thus, the cracked downward gap at USD 9.48 could also be closed. With regard to the trend-following indicator MACD, a fresh buy signal was generated only on a weekly basis. In addition, the next important resistance is the downward trend formed since the high at currently USD 13.02.

    After the month-long price disaster, analysts from Bank of America are now also speaking out with an initial assessment of the Palantir share. Mariana Perez Mora, an analyst at Bank of America, sees the US software company as a beneficiary of "rapidly growing demand" for artificial intelligence platforms in both commercial and government end markets. The dominant position held by the Palo Alto company should enable CEO Alex Karp's goal of generating at least 30% revenue growth while profits rise. The analyst's initial rating is "buy," with a price target set at USD 13.

    In contrast, the news that the data analytics company is cooperating with Google went more or less under the radar but could become more and more important in the future. According to the Alphabet subsidiary, a long-running partnership will support the digital transformation "in important sectors of the economy". Palantir is making its Foundry platform available via Google Cloud. That should enable users to better analyze and merge their data. The idea that Palantir could become a future takeover candidate for Alphabet does not sound illogical.

    New vaccine - A new wave of buying?

    Despite a correction of around 75%, the market capitalization of the "One Product" company BioNTech is still a whopping EUR 32.57 billion. Although the Mainz-based company is researching cancer vaccines based on mRNA technology, a breakthrough is still years away. The vaccine developers are now achieving this with US cooperation partner Pfizer with regard to the Omicron variant that appeared at the end of last year. The companies announced on Saturday that two adapted vaccine candidates have triggered a strong immune response in the test phase. As a result, approval should follow soon, securing the vaccine subscription for the 2022 winter season. On Tuesday, the FDA will meet with experts to discuss the optimal composition of the fall vaccine.

    "Based on these results, we believe we have developed two very good Omicron-adapted vaccine candidates that elicit a significantly higher immune response to Omicron than what we have seen before," Pfizer CEO Albert Bourla said. BioNTech CEO Ugur Sahin stated, "Omicron has continuously evolving subvariants that displace BA.1 and tend to have increased potential to evade the immune system." From a technical perspective, the stock could hold the critical support at EUR 131. In addition, the indicator situation could brighten up significantly, which means that trading gains are within the realm of possibility, at least in the short term.


    The sharp correction offers interesting entry opportunities in technology stocks such as Palantir and BrainChip. The vaccine producer BioNTech could also see a trend reversal.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Armin Schulz on August 8th, 2022 | 12:45 CEST

    Infineon, BrainChip, Nvidia - Chip shortage will continue in 2022

    • AI
    • Technology
    • Digitization
    • chips

    The chip shortage is not only omnipresent in the automotive industry. Most recently, AOK was no longer able to issue electronic health cards to its policyholders because the chips were missing. According to McKinsey, the semiconductor industry is expected to grow by 6-8% annually until 2030. Nancy Pelosi's visit to Taiwan could further fuel the chip crisis in the future. It is important to know that the island nation produces about two-thirds of all microchips needed worldwide. There is a latent danger that China will want to annex Taiwan. The USA is already trying to make itself less dependent on Asia. To that end, a USD 369 billion semiconductor manufacturing stimulus bill has been passed by Congress. Today we look at three companies that will benefit from the investment.

    Read

    Commented by Juliane Zielonka on August 5th, 2022 | 11:54 CEST

    Meta Materials, JinkoSolar, BioNTech - Smart technologies as growth boosters

    • Innovations
    • Technology
    • metamaterials
    • Biotechnology

    Solar and photovoltaic companies have been hot in the financial markets since the shifts in the energy market. Chinese supplier JinkoSolar, for example, is now launching solar batteries for home use. Smart buildings are an important component in urban city planning. Where there is plenty of sunshine, its energy is converted for personal use, and Australian residents are benefiting from JinkoSolar's technology. In order to increase the efficiency of such energy sources, Meta Materials offers innovative solutions that make solar systems even more cost-effective. Thanks to numerous patents, they also have a business model, which will please long-term investors in terms of growth opportunities. Rather unpleasant, however, are the measures planned by the German government for the coming fall and winter. Masks or vaccination is the calculation, which will at least bring some joy to BioNTech shareholders.

    Read

    Commented by Stefan Feulner on August 4th, 2022 | 13:53 CEST

    Crash! Which shares are attractive now - TeamViewer, Viva Gold, Infineon

    • Mining
    • Gold
    • Technology
    • Investments

    The technology sector has been in a sharp correction for months. The leading technology index from the US alone, the Nasdaq-100, recorded price losses of around 34% up to its low. Since the middle of last month, a countermovement has set in. However, many companies are still at an interesting entry level. Currently, the season for the publication of the figures for the second quarter is also underway. Here it becomes clear which companies you can build on in the future or which title you should remove from your portfolio.

    Read